Flusso runs institutional fundraising for exceptional companies from seed to late stage, with life sciences as its deepest specialty. Every mandate is vetted and prepared before it reaches a fund. Most of what approaches us goes nowhere. What reaches you is the fraction aligned to how you underwrite risk, sector, stage, check size, and fit.
Screening is the most expensive thing a fund does that never shows up as a line item. Analyst hours on decks that die at the first data-room question. Partner meetings that exist to establish basics a one-pager should have carried. Numbers that fall apart on first contact, after three people have already touched them.
And screening cuts both ways. The deals worth the time arrive looking identical to the ones that aren't, same templates, same confident numbers. The good deal sits unread while the dead one eats a week. That miss never appears in any report. It appears in someone else's portfolio.
Both sides of the table, three continents, one bar for what moves.

Founder and Managing Director of Flusso. Trained in medicine. Leads every fundraising mandate.

Four decades on Wall Street, from Salomon Brothers. $1B+ personally raised.

25 years in US tech, early at Yelp, LinkedIn, and Skype. Active VC at K2X Capital and venture builder.
Before anything moves toward an investor, it clears the same review:
Claims, the development path, and financing logic are checked against source, not only the founder's deck.
Ownership, prior terms, and any structure an IC would flag, checked before distribution.
We pressure-test the case against the objections your committee will raise, before you raise them.
Raise size, use of funds, and timeline that map to the next value step. A raise with a plan behind it, not a random number.
Responsive, prepared, and realistic on terms. If they cannot run our process, they will not survive yours.
Questions answered same day, data-room gaps closed before you find them, a process that doesn't stall.
Nothing goes out broadside. Every send is matched to your mandate: stage, sector or therapeutic fit, check size, and how you underwrite risk. If we cannot say why it fits your fund, it does not reach your fund.
By the time a deal reaches you, we have been inside it for weeks: the science or product, the development path, the financing logic. Your diligence questions have answers on day one, not in week three.
Decline in one line, with or without a reason. No chase sequence, no “just circling back,” no pressure to stay warm for our sake. A no ends cleanly, and your relationship with us does not depend on taking every meeting.
What you pass on, what you ask about, what almost worked. It all feeds the mandate profile, so each send fits tighter than the last. The next deal you see from us will be better.
Tell us your mandate once. From then on, you hear from us when something clears the bar and fits, with the reasoning attached. When nothing fits, you hear nothing. Silence means we're screening, not that we forgot you.
There's no fee, no commitment, and no deal you're obligated to look at. You're not subscribing to anything. You're telling us what would have to be true for a deal to be worth your time, and we only show up when it is.